| Literature DB >> 33936792 |
Suman Mewa Kinoo1, Savania Nagiah2, Anil Chuturgoon3, Bhugwan Singh1.
Abstract
BACKGROUND: The incidence of metabolic disorders in human immunodeficiency virus (HIV) endemic settings is a prevailing burden in developing countries. Cholesterol homeostasis and fat metabolism are altered by HIV and antiretroviral therapy (ART), thereby possibly contributing to complications such as gallstone formation.Entities:
Keywords: ART; ARV-induced cholesterol gallstones; HIV; HIV-induced cholesterol gallstones; cholesterol gallstones; gallstone disease
Year: 2021 PMID: 33936792 PMCID: PMC8063772 DOI: 10.4102/sajhivmed.v22i1.1208
Source DB: PubMed Journal: South Afr J HIV Med ISSN: 1608-9693 Impact factor: 2.744
Demographics and clinical parameters of study sample.
| Baseline characteristic | HIV-negative ( | WLHIV ( | |||
|---|---|---|---|---|---|
| % | % | ||||
| Median (Q1–Q3) | 50 (31–58) | - | 35 (29–42) | - | 0.015 |
| < 25 | 4 | 12 | 5 | 36 | - |
| ≥ 25 | 30 | 88 | 9 | 64 | 0.099 |
| No | 22 | 65 | 14 | 78 | - |
| Yes | 12 | 35 | 4 | 22 | 0.331 |
| Negative | 2 | 6 | 2 | 14 | - |
| Positive | 29 | 94 | 12 | 86 | 0.578 |
| None | 23 | 74 | 13 | 93 | - |
| Positive | 8 | 26 | 1 | 7 | 0.236 |
Data missing for:
, four;
, seven;
, seven women.
BMI, body mass index; WLHIV, women living with HIV.
Demographics and clinical parameters of women living with HIV with gallstones.
| Baseline characteristic | On ART ( | ART naïve ( | ||
|---|---|---|---|---|
| % | % | |||
| Median (Q1–Q3) | 38 (29–42) | - | 30 (28–31) | - |
| < 25 | 4 | 36 | 1 | 33 |
| ≥ 25 | 7 | 64 | 2 | 67 |
| No | 9 | 69 | 4 | 100 |
| Yes | 4 | 31 | 0 | 0 |
| Negative | 1 | 10 | 1 | 25 |
| Positive | 9 | 90 | 3 | 75 |
| None | 10 | 100 | 3 | 75 |
| Positive | 0 | 0 | 1 | 1 |
Data missing for:
, three;
, three;
, three women.
BMI, body mass index; ART, antiretroviral therapy.
FIGURE 1Comparative age in human immunodeficiency virus-negative individuals undergoing cholecystectomy compared to women living with human immunodeficiency virus.
FIGURE 2Body mass index comparison of human immunodeficiency virus-negative and women living with human immunodeficiency virus patients in the normal (< 25), overweight/obese (> 25) categories.
Median lipogram values.
| Parameters | Negative ( | WLHIV ( | |
|---|---|---|---|
| Median (Q1–Q3) | 4.73 (3.74–5.51) | 4.59 (4.18–5.47) | 0.766 |
| Median(Q1–Q3) | 1.12 (0.67–1.45) | 1.04 (0.84–1.33) | 0.670 |
| Median (Q1–Q3) | 1.18 (0.94–1.35) | 0.94 (0.91–1.32) | 0.866 |
| Median (Q1–Q3) | 2.85 (2.37–3.77) | 3.24 (2.93–3.74) | 0.167 |
Data missing for:
, four;
, five;
, five;
, six women.
LDL, low-density lipoprotein; HDL, high-density lipoprotein; WLHIV, women living with HIV.
Percentage of patients with abnormal lipogram values.
| Parameters (normal values) | Negative ( | Positive ( | |
|---|---|---|---|
| Normal (< 5 mmol/L) | 19 (63%) | 12 (67%) | |
| Abnormal | 11 (37%) | 6 (33%) | 0.815 |
| Normal (< 1.7 mmol/L) | 23 (79%) | 15 (83%) | |
| Abnormal | 6 (21%) | 3 (17%) | 1.000 |
| Normal (> 1.2 mmol/L) | 14 (50%) | 5 (29%) | |
| Abnormal | 14 (50%) | 12 (71%) | 0.175 |
| Normal (< 3 mmol/L) | 16 (57%) | 6 (35%) | |
| Abnormal | 12 (43%) | 11 (65%) | 0.155 |
Data missing for:
, four;
, five;
, seven;
, seven women.
LDL, low-density lipoprotein; HDL, high-density lipoprotein.